ICU Medical, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report; the filing text does not provide a clear set of Q4-only results. ICU Medical develops, manufactures, and sells infusion therapy, IV solutions, pharmacy compounding, and critical-care products.
Financial performance
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $1,316.3 million | $1,271.0 million | +3.6% |
| Gross profit / margin | $491.5 million / 37.3% | $461.5 million / 36.3% | +6.5%; margin +1.0 percentage point |
| Operating income / margin | $123.2 million / 9.4% | $98.2 million / 7.7% | +25.6% |
| Net income / margin | $103.1 million / 7.8% | $86.9 million / 6.8% | +18.7% |
| Diluted EPS | $4.74 | $4.02 | +17.9% |
| Cash from operations | $267.5 million | $222.8 million | +$44.8 million |
| Capital expenditures | $68.5 million | $92.0 million | -$23.5 million |
Cash flow and liquidity: Approximate operating cash flow less property, plant, and equipment purchases was $199.0 million in 2021. Cash and cash equivalents plus investment securities totaled $567.2 million at year-end, up from $410.8 million. Current assets were $1,029.8 million and current liabilities $200.8 million. No borrowings were outstanding on the $150 million revolving credit facility at year-end.
Debt and subsequent financing: On January 6, 2022, ICU Medical closed the Smiths Medical acquisition and entered into $2.2 billion of senior secured facilities: $850 million Term Loan A, $850 million Term Loan B, and a $500 million revolver. The term loans totaled $1.7 billion at the report date; the revolver had no borrowings. These post-year-end borrowings are not year-end 2021 debt.
Material changes versus 2020
- Infusion Consumables revenue rose 17.2% to $555.2 million, benefiting from recovery from lower hospital activity in 2020 and growth in oncology, U.S. core infusion, and renal products.
- Infusion Systems revenue fell 2.1% to $352.3 million, reflecting unusually strong COVID-related large-volume pump purchases in 2020 and lower non-large-volume pump sales; higher dedicated-set sales partly offset the decline.
- IV Solutions revenue fell 7.6% to $359.5 million, due mainly to lower Pfizer contract-manufacturing sales and supply constraints. Critical Care revenue increased 1.4% to $49.3 million.
- Gross margin improved on product mix and higher plant volumes, partly offset by higher raw-material, labor, and freight costs. SG&A rose 6.5% to $302.6 million and R&D rose 10.7% to $47.5 million.
- Restructuring, strategic transaction, and integration expenses declined to $18.0 million from $28.4 million. The company paid the $26.3 million Pursuit earn-out; an arbitrator ruled Pfizer was not entitled to a payment under the Hospira Infusion Systems earn-out dispute.
Outlook, risks, and unusual items
- Smiths Medical: The acquisition closed after year-end for approximately $1.9 billion cash, 2.5 million ICU Medical shares, and a potential $100 million contingent payment. Smiths Medical results are to be consolidated beginning in Q1 2022. Management cited broader products and global reach as strategic benefits, while warning that integration may be difficult, costly, or delayed.
- Spending outlook: Management estimated 2022 capital expenditures of $100–$120 million and restructuring, integration, and quality-compliance investments of $200–$300 million over the three years following the acquisition. No specific revenue or earnings guidance is provided in the filing.
- Operating risks: COVID-19 effects remained uncertain, with potential demand volatility, hospital access limitations, labor and supply disruptions, and higher costs. ICU Medical also cited inflation in materials, freight, and labor; sole-source suppliers; manufacturing concentration; competitive and pricing pressure; regulatory and reimbursement changes; cybersecurity and foreign-exchange exposure.
- Regulatory and product matters: Smiths Medical received an FDA Warning Letter in October 2021 relating to medical-device reporting and quality-system issues, and had initiated a Class I Medfusion Syringe Pump recall in 2020. The filing says resolution is not assured within a particular time frame.
- Financial risks and commitments: The new variable-rate debt increases interest-rate exposure, partly addressed by forward-starting swaps. The company estimated $200–$300 million of post-acquisition integration and quality investments; a 2022 Pfizer product addendum includes a $29.6 million minimum purchase obligation. The company reported no material adverse impact expected from routine unsettled legal proceedings.
- Audit and controls: The auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Revenue chargeback reserves were identified as a critical audit matter because their estimation involves judgment.
Important facts for investors to verify
- Track Smiths Medical integration, acquired-business performance, and the accounting for purchase price, contingent consideration, and integration costs.
- Monitor post-acquisition leverage, debt service, covenant headroom, interest expense, and the effect of variable rates despite hedges.
- Assess whether supply constraints and cost inflation persist and whether the company can protect gross margins under long-term customer contracts.
- Follow the Smiths Medical FDA Warning Letter and Medfusion recall status, as well as compliance with evolving device regulations.
- Review segment revenue trends, particularly IV Solutions declines and the sustainability of Infusion Consumables growth, alongside working capital and operating cash conversion.